Combination active in advanced classic Hodgkin lymphoma
Click Here to Manage Email Alerts
The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.
Nearly all (93%) patients treated with the combination responded to therapy and 88% achieved complete response, results of a multicenter phase 2 study presented at ASH Annual Meeting and Exposition showed.
The regimen exhibited a manageable toxicity profile, according to investigators.
Researcher Mitul Gandhi, MD, hematologist and oncologist at Virginia Cancer Specialists — part of US Oncology Network — spoke with Healio about the study results and their potential implications.
Collapse
Lee H, et al. Abstract 314. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Read more about
Click Here to Manage Email Alerts